Company: HRTX
Filing Date: 2025-09-19
Form Type: DEF 14A
Source: 0001193125-25-209064
Chunk: 8

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-09-19
Form: DEF 14A
Chunk 8
---
. Therefore, abstentions will have no effect on Proposals 1 and 2.

A quorum of stockholders is necessary to hold a valid meeting. A quorum will be present if at least a majority of the shares issued and outstanding and entitled to vote at the Special Meeting as of the close of business on the Record Date are represented by stockholders present at the Special Meeting or represented by proxy. At the close of business on the Record Date, there were 183,314,409 shares outstanding and entitled to vote.

Abstentions and broker non-votes will be counted towards the quorum requirement. If there is no quorum, a majority of the votes present at the Special Meeting may adjourn the Special Meeting to another date.

Preliminary voting results will be announced during the Special Meeting. In addition, final voting results will be published in a Current Report on Form 8-K that we expect to file within four business days after the Special Meeting. If final voting results are not available to us in time to file a Current Report on Form 8-K within four business days after the Special Meeting, we intend to file a Current Report on Form 8-K to publish preliminary results and, within four business days after the final results are known to us, file an amended report on Form 8-K to publish the final results.

<div align='center'>8

PROPOSAL 1 - APPROVAL OF SHARE ISSUANCES UNDER CONVERTIBLE SENIOR UNSECURED PROMISSORY NOTES</div>

On August 8, 2025, the Company entered into (i) an amendment (the “Second Amendment”) to that certain Working Capital Facility Agreement, dated August 9, 2023 (as amended, the “Loan Agreement”), with Hercules Capital, Inc., as administrative agent, collateral agent and lender. The Second Amendment amends the Loan Agreement (a) to increase the aggregate principal amount of term loans of up to $150.0 million plus accrued and unpaid paid-in-kind interest on the borrowings under the Loan Agreement prior to the Closing Date (the “existing debt”), with $110.0 million plus accrued and unpaid paid-in-kind interest on the existing debt funded on August 12, 2025 (the “Closing Date” and such transaction, the “Secured Debt Transaction”); (ii) an exchange agreement (the “Exchange Agreement”) with the investors party thereto (collectively, the “Existing Note Holders”), pursuant to which the Company and the Existing Note Holders have